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Abstract The keratins are the typical intermediate Wla-
ment proteins of epithelia, showing an outstanding degree of
molecular diversity. Heteropolymeric Wlaments are formed
by pairing of type I and type II molecules. In humans 54
functional keratin genes exist. They are expressed in highly
speciWc patterns related to the epithelial type and stage of
cellular diVerentiation. About half of all keratins—including
numerous keratins characterized only recently—are
restricted to the various compartments of hair follicles. As
part of the epithelial cytoskeleton, keratins are important for
the mechanical stability and integrity of epithelial cells and
tissues. Moreover, some keratins also have regulatory func-
tions and are involved in intracellular signaling pathways,
e.g. protection from stress, wound healing, and apoptosis.
Applying the new consensus nomenclature, this article sum-
marizes, for all human keratins, their cell type and tissue dis-
tribution and their functional signiWcance in relation to
transgenic mouse models and human hereditary keratin dis-
eases. Furthermore, since keratins also exhibit characteristic
expression patterns in human tumors, several of them (nota-
bly K5, K7, K8/K18, K19, and K20) have great importance
in immunohistochemical tumor diagnosis of carcinomas, in
particular of unclear metastases and in precise classiWcation
and subtyping. Future research might open further Welds of
clinical application for this remarkable protein family.
Keywords Keratins · DiVerentiation · Cytoskeleton · 
Tumor markers
Introduction
Most eukaryotic cells contain in their cytoplasm a more or
less elaborated cytoskeletal system consisting of intermediate
Wlaments (IF), which are chemically very stable long and
unbranched  Wlaments of »10 nm in diameter. Among the
various families and subfamilies of IF proteins, that of the
keratins is outstanding due to its high molecular diversity.
The keratin gene family consists of the highest number of
members in humans with 54 distinct functional genes. IF pro-
teins are expressed in a highly cell type-speciWc manner, and
herein keratins represent the typical IF category of epithelial
cells. In some but not all epithelia, keratin Wlaments are con-
spicuously bundled as tonoWlaments. Figure 1 shows these
keratin Wlament bundles at the light microscopical (Fig. 1a,
b) and the electron microscopical level (Fig. 1c, d). Inside the
cell they braid the nucleus (Fig. 1a), span through the cyto-
plasm and are attached to the cytoplasmic plaques of the
typical epithelial cell–cell junctions, the desmosomes (Fig. 1b,
d; for a recent review, see Waschke 2008). This feature
already suggests that keratins play a major functional role in
the integrity and mechanical stability of both the single epi-
thelial cells and, via cell–cell contacts, of that of the epithelial
tissues. Consequently, they are inherent part of the contin-
uum of stability from the single cell to the tissue formation.
Evidence for this main function of keratin Wlaments has been
amply provided by the recognition of various hereditary
keratin diseases and transgenic mouse models. In addition,
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however, various regulatory functions have been discovered
more recently (for recent reviews, see Magin et al. 2007;
Oshima 2007; Uitto et al. 2007; McLean and Irvine 2007).
Historically, keratin research started with studies of
sheep hair (wool) keratins (Crick 1952; Powell and Rogers
1986; Oshima 2007). Several important discoveries were
Fig. 1 Cytoskeleton of epithe-
lial cells. a ImmunoXuorescence 
staining of keratin K18 (red, nu-
clei stained in blue by DAPI) in 
PLC (liver carcinoma) cells in 
vitro. b Keratin Wlaments 
(in red) and the desmosomal 
component desmoplakin (in 
green) are labeled in cultured 
keratinocytes of line HaCaT. 
c Electron microscopic image of 
tonoWlament (keratin) bundles 
(arrowhead) of HaCaT keratino-
cytes. d Keratin intermediate 
Wlaments (black arrowhead) 
insert at desmosomes (white 
arrowhead) at cell–cell contact 
sites of keratinocytes of the 
epidermal stratum spinosum 
(electron microscopy)Histochem Cell Biol (2008) 129:705–733 707
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made in the 1970s of the last century. One was the Wnding
of the spontaneous self-assembly and polymerization of
keratin Wlaments from denatured, soluble keratin proteins
by dialysis in vitro (Steinert et al. 1976). Further milestones
were the Wndings that antibodies against keratins from epi-
dermis-type epithelia such as the bovine muzzle (“prekera-
tin”) react with tonoWlaments in various epithelial cells
including non-stratiWed “simple” epithelia of inner organs
(Franke et al. 1978), and that keratins of various mamma-
lian species exhibit a high degree of molecular diversity
with diVerentiation-speciWc expression (Franke et al. 1981).
Systematic protein biochemical analyses of human cells
and tissues by one- and two-dimensional gel electrophore-
sis, Western blotting and peptide mapping disclosed the
diversity of human (cyto)keratin polypeptides (Moll et al.
1982b; Tseng et al. 1982; Wu et al. 1982). From these data,
in 1982, the catalog of human cytokeratins including 19
members was proposed (Moll et al. 1982b) which, although
intended as provisional, has been widely accepted and used.
Along with these studies and subsequently, the principle of
separation of these proteins into type I (“acidic”) and type
II (“basic to neutral”) keratins (see below) also emerged.
Another unique property of the keratins is that in contrast to
the other IF proteins they only can constitute their Wlamen-
tous stage by heteropolymeric pair formation of type I and
type II (1:1) molecules. Later on, several new keratins were
identiWed and added to the cytokeratin catalog, the most
notable of these being the simple-epithelial keratin 20
(K20; Moll et al. 1990, 1992) and several keratins speciWc
for distinct epithelia such as keratin K2e in the upper epi-
dermis (appendix “e”; now K2), K2p in the upper hard
palate epithelium (similar to K2e but with appendix “p” for
palate; now K76) (Collin et al. 1992a, b), or several keratin
K6 (K6a–h) isoforms (Takahashi et al. 1995). Simulta-
neously, informations about the keratin gene sequences
were revealed.
Moreover, within the last 10 years a large number of hair
follicle-speciWc epithelial keratins were discovered. This
series started with K6hf (appendix “hf” stands for “hair fol-
licle expression”, now K75), which was expressed in the
hair follicle companion layer (Winter et al. 1998). K75 was
the Wrst epithelial keratin speciWcally expressed in the hair
follicle. Surprisingly, there were much more epithelial ker-
atins with hair follicle speciWcity, namely the type II kera-
tins K6irs1, K6irs2, K6irs3 and K6irs4 (now K71–K74)
and type I keratins K25irs1, K25irs2, K25irs3 and K25irs4
(now K25–K28), all of them speciWcally expressed in and
closely restricted to the various compartments of the hair
follicle inner root sheath (Langbein et al. 2002, 2003, 2006;
for review see Langbein and Schweizer 2005). Besides the
variety of epithelial (“soft” or “cyto-”) keratins, hairs and
nails are built up from a somewhat separate subfamily of
“hard” or “trichocytic” keratins, commonly designated as
hair keratins (Heid et al. 1988a; Langbein et al. 1999, 2001,
2004; Langbein and Schweizer 2005; Schweizer et al.
2007). They diVer from the epithelial keratins by their con-
siderably higher sulfur content in their non--helical head
and tail domains, which is mainly responsible for the
extraordinary high degree of Wlamentous cross-linking by
keratin-associated proteins (KAPs) (for review, see Rogers
et al. 2006).
Very recently, the “Keratin Nomenclature Committee”
established the novel consensus nomenclature for mamma-
lian keratin genes and proteins (Schweizer et al. 2006),
relying upon and systematically extending the aforemen-
tioned 1982 catalog. This nomenclature is now in accor-
dance with the nomenclature of the Human Genome
Organization (HUGO) for both the gene and protein names.
Following the uniWed new principles, several parts of the
former nomenclature were implemented; the hair keratins
(e.g. “Ha” and “Hb”) and the special epithelial keratin des-
ignations (e.g. K2p, K6hf, K6irs, K25irs) were equally inte-
grated (see Table 1), and the nomenclature system—
although now complete for humans—is open to application
in other mammalian species by following the same princi-
ples. Among human keratins, the new consensus nomencla-
ture (Table 1) comprises the type I keratins K9–K10, K12–
K28, and K31–K40 (including K33a and K33b) and the
type II keratins K1–K8 (including K6a, K6b and K6c) and
K71–K86. Thus, there are 28 type I keratin genes (17 epi-
thelial keratins and 11 hair keratins) and 26 type II keratin
genes (20 epithelial keratins and 6 hair keratins). All in all,
out of the 54 human keratin genes, at least 26 (»50%) are
speciWcally expressed in the hair follicle. In the human
genome, the keratin genes are clustered at two diVerent
chromosomal sites: chromosome 17q21.2 (type I keratins,
except K18) and chromosome 12q13.13 (type II keratins
including K18). The keratin genes are designated as KRT1,
KRT2, KRT3, etc. (Schweizer et al. 2006; Fig. 2a).
All these keratins belong to the family of IF proteins and
therefore share common protein-structural characteristics.
They contain a central rod domain of »310 amino acids
with  -helical conformation Xanked by non-helical head
and tail domains of variable length. The head domain con-
sists of subdomains V1 and H1. The central -helical rod
domain is composed of subdomains 1A, 1B, 2A, and 2B
connected by the linkers L1, L12, and L2. The tail domain
then consists of subdomains H2 and V2 (Lane and McLean
2004; Parry et al. 2007; Geisler and Weber 1982). The
molecular weight of human keratins ranges from »44 to
»66 kDa (Fig. 2b). A unique feature of keratins, including
the hair keratins, is their pairing, i.e. the obligate formation
of heterodimers between one type I keratin and one type II
keratin. This occurs by association of the corresponding rod
domains in -helical coiled-coil conformation. The result-
ing heterodimers and -tetramers form the basic building708 Histochem Cell Biol (2008) 129:705–733
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units of the keratin Wlaments. Single keratin proteins deviating
from equimolar type I/type II amounts are rapidly degraded
(Lu and Lane 1990).
As keratin Wlaments are important structural stabilizers
of epithelial cells, there is unabatedly high interest in kera-
tins in biology, embryology, pathology, and dermatology.
Notably, this main cytoskeletal function transcends the sin-
gle cell level. Typically, keratin Wlaments insert at desmo-
somes (Fig. 1b, d) and hemidesmosomes. Thus, they
contribute not only to the stability between epithelial cells
itself but also to basement membrane attachment and inso-
far to the connective tissue compartment of a given epithe-
lium. In the non-stratiWed (simple) epithelia of internal
parenchymatous organs, which experience little mechanical
stress, only very few keratin members form sparse and
loosely distributed keratin Wlaments in the cytoplasm. Oth-
erwise, considerably more members take part on the IF
cytoskeletal composition of squamous epithelia which
increases in the corniWed stratiWed epithelia such as in the
epidermis lining the outer body surface where they are
abundant and densely bundled as tonoWlaments. The loose
Wlaments in the former case are composed of “simple-epi-
thelial keratins” like K8/K18 (and K19), while the bundled
Wlaments (tonoWlaments) in the latter case (Fig. 1c, d) are
built up from keratinocyte-type keratins such as K5/K14 in
the basal layer and—with even more pronounced bun-
dling—K1/K10 in the suprabasal layers and K2/K10 in the
uppermost ones. The “rule” that the “stronger/harder” the
epithelial structure the more keratin members are involved
culminates in the hair Wber where 17 keratins are sequen-
tially expressed. This clearly underscores the importance of
the keratins for the tissue integrity and the relevance of the
molecular diversity of keratin proteins.
The important mechanical function of stratiWed epithe-
lial- and epidermis-type keratins is evident and proven not
only through knock-out mouse models but also through
various human hereditary keratin diseases. Thus, point
mutations of distinct keratin genes now widely explain the
pathogenesis of several autosomal-dominant familial dis-
eases, many of which are blistering skin diseases. The most
well known of these inherited skin fragility disorders is epi-
dermolysis bullosa simplex (EBS), the various variants of
which are caused by a spectrum of point mutations of K5 or
K14 (Lane and McLean 2004; McLean and Irvine 2007;
Uitto et al. 2007). Nineteen diVerent keratin genes includ-
ing hair keratins and hair follicle-speciWc epithelial keratins
have up to now been identiWed as being involved in patho-
genic keratin mutations (Lane and McLean 2004; Schwe-
izer et al. 2007); they will be discussed in the descriptions
of the individual keratins below. Updated details may be
retrieved from an Internet database (Human Intermediate
Filament Database; http://www.interfil.org). Notably, the
knock-out experiments and the genetic diseases demon-
strated that mutations in keratin genes often (depending on
the locus of mutation within the keratin molecule) cause
more severe defects than the complete loss of a keratin gene
whose failure might be compensated—if available at this
site—by another/other keratin/s.
Moreover, it has been recognized that keratins are not
simply static intracellular skeletal structures but rather are
highly dynamic. Along with this view, besides their
mechanical function new functional roles of keratins have
been deWned and still emerge under special physiological
conditions (Magin et al. 2007; Oshima 2007). These
include the protection of the placental and trophoblast bar-
rier function (K8/K18/K19: Jaquemar et al. 2003; Hesse
et al. 2000), the protection from apoptosis (K8: Caulin et al.
2000; Ku et al. 2003b; K17: Tong and Coulombe 2006), the
protection of the liver against stress and from injury (K8/
K18: Zatloukal et al. 2000; Ku et al. 2003a), and the regula-
tion of protein synthesis and cell size during wound healing
Table 1 The new human keratin nomenclature (Schweizer et al.
2006)
For K1–K20 (in gray), the numbering of the original catalog (Moll
et al. 1982b, 1990) has been maintained. The respective gene names
(“KRT”) by the human genome consortium utilize the same numbers,
e.g. “KRT20”Histochem Cell Biol (2008) 129:705–733 709
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involving intracellular signaling pathways (K17: Kim et al.
2006). Keratins may also play a role in epithelial polarity
and membrane traYc (Oriolo et al. 2007). Thus, keratins
obviously exert widely varying signaling functions beyond
their mechanical roles.
Beyond their biological functions, keratin expression
patterns not only characterize cells as “epithelial”, they are
also characteristic for distinct—including the terminal—
stages during cellular epithelial diVerentiation from embry-
onal to adult or of the internal maturation program during
development. Epithelial tumors—including metastases—
most widely retain the keratin patterns of their (normal)
epithelial origin; thus, the determination of the keratin pat-
terns of tumors are being widely exploited for cell and
tumor typing. Therefore, keratins have evolved to be one of
the most potent epithelial diVerentiation and tumor markers
in cell biology, embryology, and surgical pathology. Spe-
ciWc antibodies against several keratins are routinely used
world wide in pathology laboratories for immunohisto-
chemical typing of carcinomas in tumor diagnostics.
Numerous papers published since 1980 deal with the appli-
cation of keratins as marker proteins in tumor pathology
(Oshima 2007), and several previous review articles (e.g.
Lane and Alexander 1990; Nagle 1994; Schaafsma and
Ramaekers 1994; Moll 1998; Chu and Weiss 2002b) cover
this Weld of application, which also will be especially con-
sidered in this review.
Another clinical application is the detection of soluble
keratin protein fragments derived from K8, K18, and K19
in the circulation of cancer patients; such fragments—
released by carcinoma cells—are increasingly used to
monitor tumor load and disease progression in the case of
Fig. 2 Human keratins. a Orga-
nization of the human keratin 
genes in the genome. The type I 
and type II keratin gene subdo-
mains are located on chromo-
somes 17 and 12, respectively. 
The type I keratin K18 is located 
in the type II cluster on chromo-
some 17 (arrow). b Two-dimen-
sional catalog of the human 
keratin proteins according to 
molecular weights (MW) and 
isoelectric points (IEP) as calcu-
lated from amino acid sequenc-
es. The keratin genes are 
designated according to the new 
keratin nomenclature (Schweiz-
er et al. 2006)710 Histochem Cell Biol (2008) 129:705–733
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certain carcinomas such as non-small cell lung cancer
(Barak et al. 2004; Linder 2007). Through analysis of
diVerent K18 fragments in the serum it is also possible to
assess the type of chemotherapy-induced tumor cell death
and distinguish between apoptosis and necrosis, due to the
fact that K18 is cleaved at speciWc sites during apoptosis
and a monoclonal antibody (M30) speciWc for caspase-
cleaved forms of K8 is available (Leers et al. 1999; Linder
et al. 2004; Linder 2007).
Human keratins and their expression patterns
In the following, the diVerent human keratins and keratin
pairs will be discussed together with their cell type and tis-
sue distribution (summarized in Table 2) and their func-
tional signiWcance in relation to transgenic mouse models
and human hereditary keratin diseases. Furthermore, char-
acteristic expression patterns in human tumors (summa-
rized in Table 3) and their possible diagnostic relevance
will be considered.
Simple (one-layered) epithelia
K8/K18: primary keratins of simple epithelial cells
The keratins K8 and K18 typically are co-expressed and
constitute the primary keratin pair of simple epithelial cells,
including various parenchymatous epithelia (Franke et al.
1981; Moll et al. 1982b; Owens and Lane 2003). They are
the Wrst keratins to appear in embryogenesis, as early as in
pre-implantation embryos (Jackson et al. 1980), and also
seem to be the oldest keratins during phylogenesis (Blu-
menberg 1988). In some epithelial cell types, K8 and K18
are the sole keratins present. The classical example is the
liver, with K8/K18 representing the characteristic and only
keratin pair of normal hepatocytes. The same is true for
other highly specialized parenchymatous epithelia such as
acinar cells of the pancreas, proximal tubular epithelial
cells of the kidney, and certain endocrine cells such as pan-
creatic islet cells. Ultrastructurally, keratin Wlaments of this
simple composition are loosely distributed within the cyto-
plasm and show little bundling. In other simple, one-lay-
ered epithelia such as duct-lining cells, intestinal cells, and
mesothelial cells, additional simple-epithelial keratins (K7,
K19, and/or K20; see below) are present in addition to the
primary pair K8/K18. Furthermore, K8/K18 occur—
together with other keratins—in various pseudostratiWed
(e.g. respiratory) and complex (e.g. glandular) epithelia and
in the urothelium; in these composite epithelial tissues, K8
and K18 are often most prominent in the lumen-lining cells.
Even in non-keratinizing stratiWed squamous epithelia, K8
and K18 may be focally expressed in the basal cell layer,
together with K19 and the constitutive stratiWed-epithelial
keratins (Bosch et al. 1988; Moll 1993). Thus, K8 and K18
are widely distributed among normal epithelial tissues
although they are absent in diVerentiating keratinocytes. It
should be noted that K8 and K18 are not strictly epithe-
lium-speciWc since expression of K8 and K18 may occur in
rare mesenchymal cells (more frequently in fetal stages)
such as certain smooth muscle cells and Wbroblastic reticu-
lum cells of lymph nodes as well as various mesenchymal
tumors including rhabdo- and leiomyosarcomas (Huitfeldt
and Brandtzaeg 1985; Franke and Moll 1987; van Muijen
et al. 1987; Jahn and Franke 1989; Knapp and Franke 1989;
Knapp et al. 1989; Jahn et al. 1993; Gould et al. 1995;
Kuruc and Franke 1988; Langbein et al. 1989), where they
are co-expressed with other intermediate Wlament types,
notably vimentin and desmin.
While highly specialized parenchymatous epithelial cells
in their normal state, such as proximal tubular cells of the
kidney, only express K8 and K18, this may change in reac-
tive conditions. Upon various types of injury such as
inXammation or atrophy these cells may additionally switch
on K7 and K19, sometimes also K17 (as well as vimentin)
and thus express four to Wve instead of two keratins (Moll
et al. 1991). This increased keratin expression appears to
parallel the reduction in the degree of diVerentiation. Thus,
the keratin pattern of a given epithelial tissue may be modu-
lated to some extent in the course of reactive changes, fre-
quently resulting in higher complexity of keratin
composition.
Already the tissue distribution of K8/K18—mainly in
internal epithelia—suggests that structural and mechanical
functions are not their key roles, although their absence or
dysfunction may be associated with hepatocyte and tropho-
blast fragility (for references, see Magin et al. 2007).
Instead, genetic knock-out experiments have revealed dis-
tinct regulatory functions of these keratins (Magin et al.
2007; Oshima 2007). They play a role in protecting the
placental barrier function (K8: Jaquemar et al. 2003) and
protecting cells—in particular liver cells—from apoptosis
(K8: Caulin et al. 2000; Ku et al. 2003b), against stress, and
from injury (K8/K18: Zatloukal et al. 2000; Ku et al.
2003a), possibly by functioning as a phosphate “sponge”
for stress-activated kinases (K8: Ku and Omary 2006).
Interestingly, K8 and K18 may play a role in the regulation
of the cell cycle, whereby phosphorylation of these keratins
and binding of 14-3-3 adaptor proteins seem to be involved
(Toivola et al. 2001; Ku et al. 2002; Margolis et al. 2006;
Galarneau et al. 2007; Magin et al. 2007). In human
pathology, defects in K8 and K18 may predispose to liver
diseases, in particular cryptogenic liver cirrhosis (Ku et al.
2003a; Zatloukal et al. 2004), as well as to chronic pancrea-
titis and inXammatory bowel disease (for references, see
Owens and Lane 2004). Altered K8 and K18 proteins,Histochem Cell Biol (2008) 129:705–733 711
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together with several stress proteins, in particular ubiquitin
and p62, constitute the hyaline protein aggregates of hepa-
tocytes of several (e.g. alcoholic) liver diseases now known
as Mallory–Denk bodies (Zatloukal et al. 2007).
In regard to malignant tumors, K8 and K18 are
expressed in most carcinomas except for some diVerenti-
ated squamous cell carcinomas. Therefore, K8 and K18
antibodies strongly stain most adenocarcinomas, hepatocel-
lular carcinomas, renal cell carcinomas, and neuroendo-
crine carcinomas. Since highly sensitive monoclonal
antibodies against these keratins are available, such as the
classical mouse monoclonal CAM5.2 clone against K8
(Makin et al. 1984) and clone Ks18.04 against K18 (Bártek
et al.  1991), these keratins may be helpful in diagnostic
immunohistochemistry in cases of carcinomas with low
keratin content such as small-cell lung cancer, to prove
their epithelial nature. Regarding carcinoma subtyping,
negative or weak/focal immunostaining for K8 and K18
may indicate squamous cell diVerentiation, although strong
expression of these keratins can occur particularly in poorly
diVerentiated squamous cell carcinomas (see below, chap-
ter “Keratins as diagnostic markers in tumor pathology”).
In the case of breast carcinomas, certain publications have
reported a correlation between the level of K8 or K18
immunostaining and a favorable prognosis for the patients
(see below, chapter “Keratins as diagnostic markers in
tumor pathology”).
Another clinical application of K8/K18 is the monitoring
of fragments of these keratins in the serum as serological
tumor markers to monitor cancer load, cancer progression,
and response to therapy. Among the oldest of these markers
are tissue polypeptide antigen (TPA) and tissue polypep-
tide-speciWc antigen (TPS) which have been recognized to
correspond to a mixture of K8, K18, and K19 (Weber et al.
1984) and to K18 (Rydlander et al. 1996), respectively (for
review, see Linder 2007). More recently, an apoptosis-spe-
ciWc fragment of K18 as detected by monoclonal antibody
M30 (Leers et al. 1999) has become of increasing interest
for distinguishing between necrosis and apoptosis and for
the evaluation of the chemotherapy response of carcinomas
by investigation of cancer patient serum, e.g. in prostate,
breast, and lung cancer (Linder et al. 2007).
K7/K19: secondary keratins of simple epithelial cells
Apart from K8/K18, keratins K7 and K19 are “additional”
(secondary) and also widely distributed simple-epithelial
keratins which are frequently but not always co-expressed.
They typically occur as a keratin pair in simple ductal
epithelia such as bile and pancreatic ducts (“ductal-type”
Table 3 Characteristic expression patterns of typical keratins in selected human carcinomas
Only diagnostically relevant data as detectable by monoclonal antibodies widely established in clinical pathology are presented (for references,
see Moll 1998; Chu and Weiss 2002b; and text). Explanation of symbols: Wlled circle, extended staining of most tumor cases; open dotted circle,
focal/heterogeneous staining of some but not all cases; open circle, no staining
a In rare cases focal staining may be observed
b Focal or extended staining in a subpopulation of tumor cases, corresponding to the basal-like phenotype
c Non-mucinous types
d Preferentially/more extended in poorly diVerentiated cases
e In rare cases focal staining may be observed; however, squamous cell carcinomas of the cervix uteri may express K7 extendedly
Keratins of simple epithelia eratins of stratified
epithelia
K8 / K18 K19 K7 K20 K5
Hepatocellular carcinoma
Colorectal adenocarcinoma
Adenocarcinoma of stomach
Ductal adenocarcinoma of pancreas
Adenocarcinoma of lung
a
Invasive ductal carcinoma of breast
b
Adenocarcinoma of endometrium
Adenocarcinoma of ovary
c a
Renal cell carcinoma, clear cell type
Renal cell carcinoma, papillary type
Renal cell carcinoma, chromophobe
type
Malignant mesothelioma
Small cell carcinoma of lung
a
Merkel cell carcinoma
a
Transitional cell carcinoma
Squamous cell carcinoma (various
sites)
d d e
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keratins). However, in several epithelia lacking K7 such as
intestinal epithelium, the type I keratin K19 must form a
pair with the sole type II keratin K8.
The type I keratin K19 is the smallest keratin and is
exceptional since it widely lacks the non--helical tail
domain typical for all other keratins (Bader et al. 1986). It
may have evolved from keratinocyte keratins (Stasiak et al.
1989). As detectable by several speciWc and well-tested
monoclonal antibodies (Karsten et al. 1985; Bártek et al.
1986; Nagle et al. 1986), K19 exhibits a rather broad tissue
distribution. It is expressed in most simple epithelia
(excluding parenchymatous cells such as hepatocytes, pan-
creatic acinar cells, and renal proximal tubular cells), nota-
bly in various ductal epithelia, in small and large intestinal
epithelium, in gastric foveolar epithelium, and in mesothe-
lium. Furthermore, it is present in most cells of pseudostrat-
iWed epithelia and urothelium as well as in basal cells of
non-keratinizing stratiWed squamous epithelia.
Functionally, keratin K19 is dispensable since K19
knock-out mice were viable, fertile, and appeared normal
(Harada et al. 1999). This is apparently due to functional
compensation by K18, since only mice, double deWcient for
K18 and K19 exhibited a severe phenotype with tropho-
blast fragility and early embryonic lethality (Hesse et al.
2000). No mutation of the human K19 gene causing a dis-
ease has yet been found (Owens and Lane 2004).
The expression of K19 may be induced in certain epithe-
lia that normally lack this keratin by pathological altera-
tions. One example is damage to renal proximal tubular
epithelia by various types of injury as discussed above
(Moll et al. 1991). K19 induction is also observed in supra-
basal stratiWed squamous epithelial cells of oral mucosa
with epithelial dysplasia (Lindberg and Rheinwald 1989;
for further references, see Moll 1998), but also with inXam-
mation (Bosch et al. 1989; Moll 1993), so that K19 cannot
be used as a speciWc marker for dysplasia in oral mucosa. In
carcinomas, K19 is widely expressed in both adenocarcino-
mas and squamous cell carcinomas and therefore is not
extensively used as an immunohistochemical marker for
carcinoma subtyping. One example for such application
may be, in liver tumors, the distinction of hepatocellular
carcinomas, which show little expression of K19, from cho-
langiocarcinomas and adenocarcinoma metastases, which
strongly stain for this keratin (Balaton et al. 1988; Gold-
stein and Bosler 2006; see Table 3). The detection of solu-
ble K19 fragments in the serum released by carcinoma cells
by the CYFRA 21-1 assay has found broad clinical applica-
tion as a marker to monitor treatment and evaluate response
to therapy and has proven particularly useful in the case of
squamous cell carcinomas of the lung (for review, see
Barak et al. 2004, Gu and Coulombe 2007).
The type II keratin K7, another “ductal-type” keratin,
has a basically similar but somewhat more restricted tissue
distribution as compared to K19 (Moll et al. 1982b; Ramae-
kers et al. 1990). Like K19, it is expressed in several simple
ductal epithelia, in mesothelium, in pseudostratiWed epithe-
lia (preferentially in luminal cells), and in urothelium but
absent in parenchymatous cells such as hepatocytes. How-
ever, K7 is sparsely expressed or absent in gastric foveolar
epithelium, intestinal epithelium, and stratiWed squamous
epithelia. Human and mouse K7 genes have been character-
ized (Glass and Fuchs 1988; Smith et al. 2002), but muta-
tions or disease associations have not yet been reported
(Owens and Lane 2004).
Several monoclonal antibodies against K7 have been
described, some of which (e.g. Ks7.18, OV-TL12/30) are
well reactive with formalin-Wxed, paraYn-embedded tis-
sues. Of these, clone OV-TL12/30 (van Niekerk et al.
1991) appears to elicit the broadest span of immunoreactiv-
ity and has found wide application in diagnostic tumor
pathology, especially in cases where primary tumors or
metastases are uncertain. Since the majority of carcinomas
are K7 positive, negative reactions are of particular diag-
nostic signiWcance. One main point of diagnostic utility of
this keratin is the negative (or weak/focal) K7 immuno-
staining in colorectal adenocarcinomas (see Fig. 3c), in
contrast to the strong staining in most other adenocarcino-
mas (see Fig. 3e; Moll et al. 1992, 1993b; Chu et al. 2000;
Chu and Weiss 2002b; Tot 2002). This is especially valu-
able for classifying adenocarcinoma metastases with regard
to their possible primary tumor. Low K7 expression (nega-
tive or weak immunostaining, or staining of a minor pro-
portion of tumor cells) is also a characteristic feature of
conventional (clear-cell) renal cell carcinomas (as opposed
to papillary and chromophobe carcinomas) (Moll 1998;
Skinnider et al. 2005) and of (non-cervical) squamous cell
carcinomas. The validity in predicting the primary tumor in
cases of unclear metastases is signiWcantly increased when
K7 is used in combination with K20 (see below) since
many carcinomas exhibit characteristic K7/K20 phenotypes
(Moll et al. 1992, Moll et al. 1993b; Chu et al. 2000; Chu
and Weiss 2002b; Tot 2002; Dabbs 2006).
K20: keratin of gastrointestinal epithelium, urothelium, 
and Merkel cells
K20 is the simple-epithelial keratin with the most restricted
expression pattern. Although it appeared in our early cyto-
skeletal preparations of intestinal epithelial cells as a quite
prominent protein spot of »46 kDa, where we tentatively
designated it as “IT protein” (from intestinal; Moll et al.
1982b), we succeeded rather late in identifying it as a type I
keratin (Moll et al. 1990). For pair formation, its type II
partner usually appears to be K8. The remarkable expres-
sion spectrum of K20 among normal tissues comprises gas-
tric foveolar epithelium (Fig. 3a) and small and large714 Histochem Cell Biol (2008) 129:705–733
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intestinal epithelium (Fig. 3b; “gastrointestinal-type” kera-
tin) and, in addition, the urothelium and certain neuroendo-
crine cells, in particular Merkel cells of the skin. In human
embryogenesis, it appears in the small intestinal epithelium
at embryonic week 8 (Moll et al. 1993b). Within the gastro-
intestinal and urothelial epithelial tissues, K20 is absent
from the stem cell compartment and appears to be switched
on during terminal diVerentiation and thus is most promi-
nent in small intestinal villus-lining and large intestinal sur-
face-lining epithelia (Fig. 3b) and in urothelial umbrella
cells. Although K20 is a keratin typically expressed in sim-
ple epithelia it is also found in the lone basally located Mer-
kel cells of the epidermis and hair follicle outer root sheath
(Moll et al. 1992, 1995).
Our knowledge about the function of K20 still is limited.
Mutations of human K20 or associated diseases have not
yet been described (Owens and Lane 2004). Transgenic
experiments suggest a role for K20 in maintaining keratin
Wlaments in intestinal epithelia (Zhou et al. 2003). In mouse
small intestinal epithelium, K20 phosphorylation on serine
13 is induced during apoptosis and tissue injury and thus
may serve as stress marker (Zhou et al. 2006).
Among the K20-speciWc monoclonal antibodies available,
clone Ks20.8 reacts well on routine paraYn sections (Moll
et al. 1992) while clone Ks20.10 reacts with the K20 homo-
logue of rodents (Moll 1993). K20 is a potent immunohisto-
chemical marker in tumor pathology since its peculiar
expression spectrum is essentially maintained in the corre-
sponding primary and metastatic carcinomas (Moll et al.
1992), and the K20 clone Ks20.8 has become part of the rou-
tine antibody panel in most pathology laboratories. Most
colorectal adenocarcinomas (Fig. 3d), the majority of gastric
adenocarcinomas, the majority of transitional cell carcino-
mas, as well as most Merkel cell carcinomas are K20-posi-
tive (Moll et al. 1992,  1993b; Miettinen 1995; Chu et al.
2000; Chu and Weiss 2002b; Goldstein and Bosler 2006). In
a few other carcinoma types, variable and focal K20 expres-
sion is seen, notably in ductal adenocarcinomas of the pan-
creas (Fig. 3f) and in adenocarcinomas of the biliary tract
including cholangiocarcinomas of the liver (Moll et al. 1992;
Miettinen 1995; Chu et al. 2000). Among ovarian carcino-
mas, K20 is mainly detected in the mucinous type. Most
other carcinomas, including adenocarcinomas, irrespective of
their morphology, are essentially negative for K20. Thus,
signiWcant K20 positivity of a metastatic adenocarcinoma is
predictive of a primary tumor in the gastrointestinal or pan-
creaticobiliary tract. It should be noted that the diagnostic
value is increased when the markers K20 and K7, are applied
Fig. 3 Keratins in simple epi-
thelia and adenocarcinomas 
(paraYn sections of human tis-
sues; avidin–biotin complex per-
oxidase staining). Keratin K20 is 
a characteristic and prominent 
keratin of the foveolar epithe-
lium of the gastric (a) and colo-
rectal (b) mucosa. The K7¡/
K20+ phenotype of the normal 
mucosa is mostly maintained in 
primary and metastatic colorec-
tal adenocarcinomas. This is 
shown here for a skin metastasis 
(on the head) of a poorly diVer-
entiated adenocarcinoma: the tu-
mor cells are negative for K7 (c) 
but positive for K20 (d, left por-
tion of the Wgure), even includ-
ing a tumor cell cluster that has 
invaded a lymphatic capillary (d, 
right upper corner). This pheno-
type is strongly suggestive of 
colorectal origin. A primary tu-
mor in the right colon was de-
tected later. Liver metastasis of a 
ductal adenocarcinoma of the 
pancreas with typical keratin 
pattern, showing extended 
expression of K7 (e) and staining 
of scattered tumor cells for K20 
(f). MagniWcations: a, d £80; b, 
c, e, f £140Histochem Cell Biol (2008) 129:705–733 715
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in combination. For example, a K7¡/K20+ phenotype of an
adenocarcinoma metastasis (Fig. 3c, d) strongly favors a
colorectal origin. Some colorectal adenocarcinomas co-
express K7 in addition to K20, but as a general rule, the level
of K20 immunostaining exceeds that of K7 (see below, chap-
ter “Keratins as diagnostic markers in tumor pathology”).
Using RT-PCR analyses, K20 mRNA can be detected in
cell preparations from bone marrow and peripheral blood
from some colorectal cancer patients, indicating the pres-
ence of disseminated tumor cells that maintain K20 expres-
sion, and a number of clinical studies have shown that this
is correlated with a worse prognosis (Soeth et al. 1996;
Funaki et al. 1998; Wyld et al. 1998; Koch et al. 2005;
Katsumata et al. 2006; Friederichs et al. 2007). In addition
to patients with metastatic colorectal carcinoma, K20
expression in the peripheral blood was also detected in
patients with metastatic gastric and pancreatic adenocarci-
noma but hardly in patients with metastatic lung carcinoma
(Chausovsky et al. 1999), underlining the tumor type-spe-
ciWc expression of this keratin.
StratiWed epithelia
K5/K14: major keratins of basal keratinocytes
The type-II keratin K5 and the type-I keratin K14 form the
primary keratin pair of the keratinocytes of stratiWed squa-
mous epithelia, including the epidermis as well as mucosal
non-keratinizing stratiWed squamous epithelia (Moll et al.
1982b). They are strongly expressed in the undiVerentiated
basal cell layer containing the stem cells and are down-regu-
lated in the diVerentiating suprabasal cell layers (Fig. 4a;
Fuchs and Green 1980). Otherwise, in the widely well strat-
iWed follicular outer root sheath, K5 and K14 are uniformly
expressed throughout all layers. Moreover, the follicular
companion layer, which is directly adjacent to the outer
root sheath (and formerly considered as “innermost layer of
the outer root sheath”), is completely negative for both of
these keratins and expresses an own special keratin, K75
(see below). Ultrastructurally, K5/K14 keratin Wlaments are
bundled as tonoWlaments and attached to desmosomes and
hemidesmosomes. The mouse K5 promoter is frequently
used in transgenic experiments to promote epidermis-spe-
ciWc expression of transgenes (e.g. Oki-Idouchi and Lore-
nzo 2007). In addition to their occurrence in keratinocytes,
K5 and K14 are expressed in basal and myoepithelial cells
of complex and glandular epithelial tissues (Purkis et al.
1990). On the other hand, these keratins are absent from
most simple/one-layered epithelia, with very few excep-
tions, notably the mesothelium lining serous cavities (Moll
et al. 1989) and the amnion epithelium.
Several monoclonal antibodies (MAbs) speciWc for K5
and K14 have been described that helped to reveal their
exact tissue distribution. These antibodies include MAb
AE14 (Moll et al. 1989) against K5 and MAbs LL001 and
LL002 against K14 (Purkis et al. 1990). The best perfor-
mance on paraYn sections is displayed by MAb D5/16B4
(Lobeck et al. 1989; Demirkesen et al. 1995) which—
although being often regarded as “K5/K6 antibody”—spe-
ciWcally recognizes K5 (Böcker et al. 2002).
The functional importance of K5 and K14 for the physi-
cal stability of the epidermis has become clearly evident by
the recognition that dominant-negative mutations of the K5
or the K14 gene cause the hereditary blistering skin disease
epidermolysis bullosa simplex (EBS) (for reviews, see
Omary et al. 2004; Lane and McLean 2004). Most of these
mutations are missense or small in-frame deletion muta-
tions, primarily aVecting the keratin rod domain. The pres-
ence of mutated K5 or K14 results in increased fragility of
the basal keratinocytes so that even mild physical trauma
leads to intraepidermal cytolysis of basal cells and the for-
mation of Xuid-Wlled blisters. These patient-related Wndings
were preceded by the experimental demonstration that
expression of mutant K14 in transgenic mice causes abnor-
malities similar to EBS (Vassar et al. 1991).
The expression spectrum of K5 and K14 in tumors corre-
sponds well to the patterns in normal epithelia. Thus, most
squamous cell carcinomas (Fig. 4c, e) as well as malignant
mesotheliomas strongly express these keratins whereas lit-
tle, focal, or no expression is found in adenocarcinomas
(Moll et al. 1982b, 1989; Moll 1998; Chu and Weiss 2002a,
b). Hence, these keratins, in particular K5, have found sev-
eral lines of diagnostic application in pathology, which has
been aided by the availability of a highly sensitive and spe-
ciWc, robust, paraYn-suited MAb (D5/16B4; see above).
Pertinent examples are the recognition and diagnosis of
poorly diVerentiated squamous cell carcinomas, including
micrometastases in lymph nodes (Fig. 4e), of undiVerenti-
ated nasopharyngeal carcinomas which may be diagnosti-
cally diYcult due to their dissociated growth pattern
(Fig. 4f), and of malignant mesotheliomas. Thus, K5 immu-
nostaining allows the distinction of the small cell type of
squamous cell carcinoma of the lung, which is K5+, from a
small cell carcinoma or a poorly diVerentiated adenocarci-
noma, both of which are K5¡ (Moll 1998; Chu and Weiss
2002a), and the distinction of a malignant mesothelioma of
the pleura (K5+) from a pulmonary adenocarcinoma with
pleural involvement (K5¡) (Moll et al. 1989; Ordonez
1998; Yaziji et al. 2006). In well and moderately diVerenti-
ated squamous cell carcinomas, K5 is preferentially localized
in the peripheral layers of the tumor cell formations
(Fig. 4c), corresponding to the K5 expression in the basal
cell layer of normal stratiWed squamous epithelia. Focal K5
expression may be observed in certain adenocarcinoma
types, notably in adenocarcinomas of the endometrium, the
ovary, and the pancreas, which seems to be related to their716 Histochem Cell Biol (2008) 129:705–733
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potency for focal squamous diVerentiation (Moll 1998; Chu
and Weiss 2002a,  2002b). Much interest has evolved
regarding the role of K5 in breast pathology in several
aspects, including the identiWcation of myoepithelial cells,
the classiWcation of proliferative lesions (Otterbach et al.
2000), and the recognition of a certain subtype of invasive
ductal breast carcinoma (see below, chapter “Keratins as
diagnostic markers in tumor pathology”). In prostate
pathology, the diagnosis of prostatic adenocarcinoma is sup-
ported by the immunohistochemical demonstration of absence
of K5-positive basal cells (Abrahams et al. 2002, 2003).
K15: basal keratinocyte keratin and hair follicle stem cell 
“marker”
K15 was Wrst identiWed as a minor keratin of human epider-
mis, by gel electrophoresis of cytoskeletal preparations
(Moll et al. 1982b, c). Its sequence demonstrated its assign-
ment to the type I keratins (Leube et al. 1988). Only later its
cellular distribution was recognized, and it was uncovered
that K15 is a speciWc basal cell component of the epidermis
(Moll et al. 1993a; Lloyd et al. 1995) and other stratiWed
squamous epithelia (Waseem et al. 1999) (see below for its
signiWcance in the hair follicle). Frequently, K5 and K14
can also be detected in the lower suprabasal cell layers (see
above and Fig. 4a). Whereas the mRNA synthesis of these
keratins is restricted to the basal layer, the K5 and K14 pro-
teins remain integrated in the complex keratin cytoskeleton
for some time when cells leave the basal compartment.
Thus, they may be stained by immunohistochemistry in
more or less suprabasal layers depending on the epitope of
the antibody used. In comparison, K15 seems completely
restricted to the basal cell layer of stratiWed squamous epi-
thelia (Lloyd et al. 1995; Waseem et al. 1999) where it can
Fig. 4 Keratins in stratiWed squamous epithelia and squamous cell
carcinomas (paraYn sections of human tissues; avidin–biotin complex
peroxidase staining). In the epidermis as an example of a normal strat-
iWed squamous epithelium, the basal cell layer contains abundant ker-
atin K5 (a) whereas the diVerentiating suprabasal compartment
strongly stains for K10 (b; note the negative basal cell layer). Lymph
node metastasis of a squamous cell carcinoma of the head and neck
region, expressing K5 (c; more intensely in the peripheral tumor cell
layers) as well as K6 (d; particularly strongly in central tumor cells) as
signs of their keratinocyte origin. Keratin K5 is also maintained in a
lymph node micrometastasis of a squamous cell carcinoma of the head
and neck region (e) and in a lymph node metastasis of an undiVerenti-
ated nasopharyngeal carcinoma with dissociated growth pattern of the
tumor cells (f), in these examples being a diagnostically helpful
feature. MagniWcations: a, b £160; c–e £80; f £140Histochem Cell Biol (2008) 129:705–733 717
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form heteropolymeric Wlaments with K5 (Lloyd et al.
1995).
MAbs recognizing K15 include clone LHK15 (Waseem
et al. 1999) and clone C8/144B (Lyle et al. 1998, 1999).
The latter in fact is a surprising and exciting MAb origi-
nally made against the lymphocyte antigen CD8 which
cross-reacts with K15 especially in the basal keratinocytes
of the hair follicle bulge region, where the respective stem
cells are assumed. Also polyclonal K15 antibodies have
furthermore been described (Moll et al. 1993a; Kurzen
et al. 2001, Langbein et al. 2008). K15 expression in basal
cells is downregulated in activated epidermal keratinocytes
such as in organotypic cultures and in hyperproliferation
(Waseem et al. 1999) or upon wounding (Porter et al.
2000). Human mutations or knock-out mice for K15 have
not yet been described.
As to the occurrence of K15 in tumors, the literature is
inconclusive as to whether there is diVerential expression of
K15 among cutaneous tumors (benign follicular tumors
versus basal cell carcinomas), possibly due to the use of
diVerent antibodies1 (see also above), and thus a putative
diagnostic application of K15 immunohistochemistry in
dermatopathology is still open (Kanitakis et al. 1999; Jih
et al.  1999; Porter et al. 2000; Kurzen et al. 2001). Cur-
rently, the most interesting feature with K15 is the discov-
ery that within the hair follicle at least one antibody against
this keratin detects putative stem cells residing in the hair
follicle bulge and thus might be used as a stem cell marker
in hair follicle biology (Lyle et al. 1999).
K6/K16: keratins of hyperproliferative keratinocytes 
inducible in “activated” epidermis
By gel electrophoresis, the type-II keratin K6 and the type-I
keratin K16 have been identiWed in epidermis only in sam-
ples from plantar glabrous skin while in hairy skin these
keratins appeared to be absent in interfollicular epidermis
but were clearly present in hair follicle outer root sheath
(Moll et al. 1982b, c; Langbein and Schweizer 2005) and
companion layer (Winter et al. 1998; Langbein and Schweizer
2005; Gu and Coulombe 2007). In nail epithelia, K6 and
K16 are constitutive components (Heid et al. 1988b; Lane
and McLean 2004; Perrin et al. 2004). K6 and K16 are also
consistently expressed in non-keratinizing stratiWed squa-
mous epithelia (Moll et al. 1982b). They are often but not
always co-expressed as a keratin pair (Moll et al. 1982b;
Langbein et al. 2005). Molecular genetic studies have
revealed that in humans three isoforms of K6 exist, K6a,
K6b, and K6c, encoded by distinct genes (Rogers et al.
2005; Schweizer et al. 2006).
MAb KA12 is an antibody which most probably stains at
least keratin K6a isoform and reacts well with paraYn sec-
tions (Demirkesen et al. 1995; Langbein et al. 2003; Sch-
melz et al. 2005) although isoform-speciWc antibodies
against K6a, K6b or K6c will hardly be made because of
their extremely high peptide sequence homology. Using
this MAb, plantar epidermis shows extended albeit hetero-
geneous expression of K6a, while interfollicular epidermis
is negative or exhibits only some positive suprabasal cell
groups (Demirkesen et al. 1995; Swensson et al. 1998).
Non-keratinizing stratiWed squamous epithelia express K6
uniformly in all suprabasal cell layers. A MAb against K16
has also been described (Leigh et al. 1995).
In early immunohistochemical studies using keratin
group-speciWc MAbs, Weiss et al. (1984) demonstrated the
induction of K6 (56-kd keratin) and K16 (48-kd keratin) in
various hyperproliferative epidermal disorders, suggesting
that these keratins may be molecular markers for hyperpro-
liferative keratinocytes. More recent experimental studies
showed that after skin wounding, K6 and K16 are rapidly
induced within 6 h in human keratinocytes at the wound
edge, before migration and regeneration begins (Paladini
et al.  1996). The particular cell biological properties of
these keratins may confer to activated keratinocytes on the
one hand a moderate level of mechanical scaVolding and on
the other hand suYcient plasticity required during migra-
tion and re-epithelialization (Wawersik et al. 2001). K6a
knockout mice showed delayed re-epithelialization after
skin wounding (Wojcik et al. 2000). Upon K6a/K6b double
knock-out, mice exhibit epithelial disintegration and white
plaques in the dorsal tongue epithelium (Wong et al. 2000;
Wojcik et al. 2001). The absence of a hair and nail pheno-
type in these mice—as might be expected from the occur-
rence of K6 in these appendages—has been shown to be
due to the presence and compensatory function of other K6-
related keratins in hair follicles and nails, such as mK6hf
(Wojcik et al. 2001; now mK75) or mK6irs1—mK6irs4
(now mK71–mK74; cf. Langbein et al. 2002, 2003).
In man, mutations in K6a or K16 have been proven to
give rise to the hereditary disorder pachyonychia congenita
type 1 (Jadassohn–Lewandowsky form) that manifests with
thickened nails, palmoplantar hyperkeratosis, and oral leu-
koplakias (McLean et al. 1995; for further references, see
Lane and McLean 2004). Notably, the pathologic changes
aVect those tissues that constitutively express K6a and K16
(see above) but not the interfollicular epidermis.
Thus, K6/K16 are constitutive keratins of stratiWed epi-
thelia built up by keratinocytes of relatively high prolifera-
tive state such as mucosal tissues, palmoplantar epidermis,
1 One principle comment has to be stated. Besides the problem, that “on
market” many antibodies (not only against keratins) sometimes are
only barely “characterized” and insofar of questionable “speciWcity”
once must keep in mind that also some of the heavily used antibodies
were never tested under the viewpoint of the today’s knowledge of all
human keratins.718 Histochem Cell Biol (2008) 129:705–733
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and certain skin appendages. On the other hand, they are
“stress-inducible” keratins in interfollicular epidermis,
being rapidly switched on e.g. after injury and UV-irradia-
tion or being present also in inXammation and in hyperpro-
liferative disorders.
Expression of these keratins is not restricted to stratiWed
squamous epithelia but may also be observed in certain
glandular structures. Thus, K6 (most probably K6a) and
K16 are expressed in ductal luminal cells as well as in some
secretory cells of human eccrine sweat glands (Fig. 5;
Demirkesen et al. 1995; Langbein et al. 2005). K6 has been
detected in subpopulations of luminal cells of the mouse
mammary gland (Grimm et al. 2006) and the human mam-
mary gland; in the latter, also in ductal myoepithelial cells
(Hesse 2003; Langbein et al. 2005). Recently, a population
of K6-positive cells in the prostate gland with high poten-
tial for proliferation and diVerentiation has been described
(Schmelz et al. 2005).
In the pseudostratiWed epithelia of respiratory mucosal
tissues, K6 and K16 are highly upregulated in squamous
Fig. 5 Keratin K77 in eccrine 
sweat glands and adnexal tu-
mors. K77 mRNA and protein 
by in situ hybridization (ISH, a, 
a) and indirect immunoXuores-
cence (IIF, b-b) microscopy. 
This keratin is speciWcally ex-
pressed in the luminal cells (lc) 
of the intraglandular (igd), the 
intradermal (idd), the sweat duct 
ridge (sdr) and the intraepider-
mal/acrosyringial (ied/ac) duct 
of eccrine sweat glands of plan-
tar skin. Peripheral duct cells are 
negative. The secretory portions 
(asterisks) are K77-negative. sb 
str. basale, ss str. spinosum, sg 
str. granulosum, sc str. corneum, 
gl glandular region with secre-
tory and intraglandular duct por-
tions. c Expression scheme of 
keratins of the eccrine sweat 
gland. d-d Immunoperoxidase 
staining of K77 in the luminal 
cells of the eccrine sweat gland 
duct of the foot sole epidermis. 
K77 is also expressed in the 
tubular structures (arrows) of 
eccrine tumors such as syrin-
goma (e) and cylindroma (f). 
Bars 100 mHistochem Cell Biol (2008) 129:705–733 719
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metaplasia (Leube and Rustad 1991; Stosiek et al. 1992).
Among tumors, K6 and K16 are typically and strongly
expressed in squamous cell carcinomas of diVerent sites
(Moll et al. 1982b; Moll 1998), preferentially in inner,
maturing layers of the tumor cell nests (Fig. 4d). Although
low expression of these keratins may be found in adenocar-
cinomas such as occasionally in adenocarcinomas of the
uterine cervix (Smedts et al. 1993) and in less than 20% of
invasive breast carcinomas (Wetzels et al. 1991), K6 as
detected by MAb KA12 may be suitable—in addition to
K5—as another immunohistochemical marker of squamous
diVerentiation in poorly diVerentiated squamous cell carci-
nomas (Moll 1998).
K17: keratin of basal/myoepithelial cells and inducible 
in “activated” keratinocytes
The type I keratin K17 was identiWed in our early gel elec-
trophoretic studies as a major keratin of basal cell carci-
nomas of the skin which was also present in the normal
pilosebaceous tract but not in normal epidermis (Moll
et al. 1982c). Further protein analyses showed its pres-
ence in squamous cell carcinomas of various origins as
well as in normal glandular tissues (such as sweat glands
and breast) but its apparent absence also from non-kerati-
nizing stratiWed squamous epithelia (Moll et al. 1982b,
1983). The unique cell type distribution of this keratin
became apparent after establishment of a speciWc MAb,
clone E3 (Troyanovsky et al. 1989). Broad tissue screen-
ing revealed its selective expression in basal and myoepi-
thelial cells of complex tissues, including various glands,
respiratory epithelium, and urothelium (Troyanovsky
et al.  1989,  1992). Thus, K17 may be regarded as a
“basal-/myoepithelial cell keratin”. In the hair follicle,
conWrming and extending previous biochemical Wndings
(Moll et al. 1982c), K17 has been localized as a prominent
component of the suprabasal cell layers of the outer follicular
root sheath (Winter et al. 1998; Langbein and Schweizer
2005; Langbein et al. 2006; Tong and Coulombe 2006).
It is also present in nail bed and nail matrix epithelia
(McGowan and Coulombe 2000; Perrin et al. 2004).
Immunohistochemistry also conWrmed the essential
absence of K17 from adult interfollicular epidermis, but,
interestingly, revealed its speciWc expression in the spe-
cialized epidermal keratinocytes of the sensory Merkel
cell-associated “haarscheiben” organs (Moll et al. 1993a);
this keratin thus may be applied as a sensitive haarschei-
ben marker in studies of cutaneous neurobiology. In con-
trast to the adult, K17 is a prominent component of fetal
epidermis (Moll et al. 1982a) as well as of cultured epi-
dermal cells (Weiss et al. 1984).
Another interesting feature of K17 is its inducibility after
skin injury: after K6/K16 (see above), K17 is switched on
in regenerating and migrating epidermal keratinocytes upon
wound healing (Paladini et al. 1996). Its functional impor-
tance in wound healing is suggested by the observation that
K17 knockout mouse embryos show a delay in the closure
of surface ectoderm wounds (Mazzalupo et al. 2003).
Recent transgenic experiments have shown that K17 can
bind to the adaptor protein 14-3-3 and inXuences cell
growth and size of mouse keratinocytes by regulating pro-
tein synthesis (Kim et al. 2006).
The aforementioned expression of K17 in the piloseba-
ceous tract (in the follicular outer root sheath, companion
layer, medulla and sebaceous gland; for review, see Lang-
bein and Schweizer 2005) has also proven to be function-
ally relevant. K17 null mice develop transient severe
alopecia in early postnatal life, correlating with hair fragil-
ity and apoptosis in hair matrix cells (McGowan et al.
2002). The same group later showed that K17 modulates
hair follicle cycling by delaying apoptosis, whereby K17 is
functionally linked with TNF signaling (Tong and Cou-
lombe 2006).
Hereditary human diseases due to K17 mutations have
been identiWed (for references, see Lane and McLean
2004), most notably pachyonychia congenita type 2 (Jack-
son–Lawler form). The phenotype of this genodermatosis
includes thickened nails and pilosebaceous cysts. Another
condition related to K17 mutations is steatocystoma multi-
plex, in which patients present with multiple hair follicle-
associated cysts. These genodermatoses obviously are
related to the expression and functional importance of K17
in pilosebaceous and nail (Perrin et al. 2004; Langbein and
Schweizer 2005) epithelia.
Since in keratinocytes K17 is—like K6 and K16 (see
above)—an inducible keratin upon stress, injury, or inXam-
mation, it is not surprising that squamous cell carcinomas
consistently express these three keratins (Moll et al. 1982b,
1983; Chu and Weiss 2002b). As mo st n orm al str atiWed
squamous epithelia lack K17, its presence in the corre-
sponding tumors may be regarded as neo-expression during
tumorigenesis. In the uterine cervix, K17 is expressed in
cervical intraepithelial neoplasia but since it is already pres-
ent in endocervical reserve cells (Weikel et al. 1987) and
immature squamous metaplasia, it has not yet become a
routine diagnostic marker (Martens et al. 1999). Among
adenocarcinomas, focal K17 expression seems to be par-
ticularly characteristic of pancreatic ductal adenocarcino-
mas (Real et al. 1993; Moll 1998), which may become
useful for their distinction from other adenocarcinomas
(Chu and Weiss 2002b). In ductal breast carcinomas, K17
is expressed in a minor subset of tumor cases (Malzahn
et al. 1998), now recognized to correspond to the basal-like
subtype as deWned by global gene expression data (see
below, chapter “Keratins as diagnostic markers in tumor
pathology”).720 Histochem Cell Biol (2008) 129:705–733
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K1/K10: major keratins of keratinocyte diVerentiation 
and keratinization
In the epidermis, the transition of keratinocytes from the
proliferative basal cell layer to the postmitotic suprabasal
spinous cell layers in the process of terminal diVerentiation
and keratinization is characterized by a profound change in
keratin expression. This involves a switch from expression
of the basal cell keratins (K5, K14, K15) to the suprabasal
epidermal keratins, the type II keratin K1 and subsequently
the type I keratin K10 (Fig. 4b; Fuchs and Green 1980; Moll
et al.  1982b; Tseng et al. 1982, Weiss et al. 1984; Roop
1987, Stoler et al. 1988). This is one of the classical exam-
ples for the carefully regulated diVerentiation-speciWc
expression of keratin proteins. Ultrastructurally, keratin Wla-
ments composed of the pair K1/K10 form particularly dense
bundles which are so characteristic of suprabasal epidermal
keratinocytes (Fig. 1d). Clearly, this imparts mechanical
integrity to the cells and the whole epidermis. In addition,
however, there seem to exist further functional roles, as
experimental data have demonstrated that K10 speciWcally
inhibits proliferation and cell cycle progression of keratino-
cytes (Paramio et al. 1999; Koch and Roop 2004) and loss of
K10 leads to increased keratinocyte turnover (Reichelt et al.
2004; for review, see Magin et al. 2007).
The importance for epidermal integrity is underscored
by the fact that point mutations in K1 and K10 are associ-
ated with the blistering disorder epidermolytic hyperkerato-
sis/bullous congenital ichthyosiform erythroderma (BCIE),
initially presenting with skin blisters but later with thick-
ened ichthyotic skin (for reviews, see Lane and McLean
2004; Omary et al. 2004). As expected, the suprabasal cells
become fragmented easily and, in addition, the epidermis
becomes hyperproliferative and hyperkeratotic. K1 muta-
tions are notably heterogeneous and may result in diverse
overlapping, often relatively mild phenotypes (Lane and
McLean 2004). In transgenic mouse experiments, mutation
or knock-out of K10 results in a phenotype similar to
human epidermolytic hyperkeratosis (Fuchs et al. 1992;
Porter et al. 1996).
Despite their association with terminal epidermal diVer-
entiation and keratinization, K1 and K10 may be focally
expressed in suprabasal cells of internal noncornifying strat-
iWed squamous epithelia (for references, see Moll 1998).
They are also a typical component of cells of eccrine sweat
gland ducts (Fig. 5; Langbein et al. 2005). Surprisingly,
although the diVerentiated parts of the hair follicle, such as
suprabasal outer root sheath, upper companion layer, upper
inner root sheath or the hair Wber, are heavily keratinized
structures, all of them are free of K1/K10. Both typical epi-
dermal keratins are completely lost in the infundibulum.
Among various antibodies against K1 and K10 described
in the literature, MAb DE-K10 against K10 is particularly
suitable for application with paraYn-embedded tissues
(Ivanyi et al. 1989). In squamous cell carcinomas focal
expression of K1 and K10, usually in relation to maturation
and keratinization, can be observed regardless of whether
they are derived from the skin or from internal organs (for
references, see Moll 1998). They are more sparse in poorly
diVerentiated tumors but may still be detected in about 50%
of cases of oral and pharyngeal squamous cell carcinomas
(Moll 1998). However, quantitatively, squamous cell carci-
nomas rather embark on an alternative maturation pathway
characterized by abundant expression of K6 and K16 (see
above; Fig. 4d). Overall, K1 and K10 can be regarded as
“keratinization markers” of keratinocytes. These keratins
have not yet been routinely applied to tumor diagnosis
except for some special aspects of skin tumors (Yuspa et al.
1991).
K9: palmoplantar epidermal diVerentiation keratin
The type I keratin K9 is a highly speciWc keratin of termi-
nally diVerentiating keratinocytes of palmoplantar epidermis
where it is abundantly, albeit heterogeneously expressed
(Moll et al. 1987; Langbein et al. 1993). At other body sites,
there may be extremely sparse and focal expression in upper
epidermal layers (Moll et al. 1987). Thus K9, forming a pair
with K1, appears to reXect a special program of keratinocyte
diVerentiation associated with particular mechanical rein-
forcement (Swensson et al. 1998). Therefore it is not surpris-
ing that mutations in the K9 gene are associated with a
disorder of the skin of the palms and soles, epidermolytic
palmoplantar keratoderma, which manifests itself as cytoly-
sis and epidermal thickening (Reis et al. 1994; Torchard
et al. 1994; for review, see Lane and McLean 2004). In its
sequence, K9 is most closely related to K10 (Langbein et al.
1993). MAbs against K9 (clones Ks9.70, Ks9.216; PRO-
GEN, Heidelberg, Germany) are available (Langbein et al.
2005, 2006, 2008). Immunostaining for K9 has signiWcance
for characterization of palmoplantar keratinocyte direction
of transplants (Compton et al. 1998; Stoner and Wood 1999)
and of special genodermatoses (McLean and Irvine 2007)
but there is no relevance of K9 in tumor diagnosis. It should
be noted that the occurrence of keratin K9 (and K1 and K10)
may give rise to problems in biochemical practice as bio-
chemicals or buVers are sometimes contaminated with these
keratins derived from abraded “horny particles”, i.e. termi-
nally diVerentiated skin keratinocytes (“laboratory dust”;
Clark et al. 1971; Fox et al. 2008).
K2: keratin of highly diVerentiated, advanced epidermal 
keratinocytes
K2 (formerly K2e, see before and Table 1) is another kera-
tin speciWc for the advanced terminal diVerentiation processHistochem Cell Biol (2008) 129:705–733 721
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of epidermal keratinocytes. Being widely distributed over
most body sites, this type II keratin is expressed late, at an
advanced stage of diVerentiation, in the uppermost epider-
mal layers (upper stratum spinosum, stratum granulosum)
to a variable extent (Collin et al. 1992a). K2 is not
expressed in follicular skin adnexal structures like the late
compartments of outer or inner root sheath. Correspond-
ingly, mutations in K2 have been associated with ichthyosis
bullosa of Siemens, a blistering disease showing cytolysis
in superWcial epidermal layers (for references, see Lane and
McLean 2004). MAbs speciWc for K2 (clones Ks2.342.7.1,
Ks2.398.3.1; PROGEN, Heidelberg, Germany) have been
described (Langbein et al. 2005, 2006, 2008).
K3/K12: keratins of the corneal epithelium
The K3 (type II)/K12 (type I) pair is the cell type-speciWc
and diVerentiation-related keratin pair of the corneal epithe-
lium. These keratins are expressed in all corneal epithelial
cell layers, whereas in the limbus corneae only suprabasal
cells are positive and the basally located corneal stem cells
are K3/K12 negative (Schermer et al. 1986; Pitz and Moll
2002). Mutations in these keratins give rise to Meesmann’s
corneal dystrophy characterized by intraepithelial micro-
cysts in the corneal epithelium (Irvine et al. 1997; for fur-
ther references, see Lane and McLean 2004). K12 knock-
out mice have a mechanically fragile, easily detachable cor-
neal epithelium (Kao et al. 1996). Antibodies against these
corneal keratins described include MAb AE5 (PROGEN,
Heidelberg, Germany) which reacts with K3 and addition-
ally with the related K76 (formerly K2p; see below; Collin
et al. 1992b) and MAb AK12 which recognizes K12 (Cha-
loin-Dufau et al. 1993).
K4/K13: keratins of mucosal stratiWed squamous epithelial 
cells
In internal stratiWed squamous epithelia which mostly are
non-keratinizing, a highly characteristic keratin pair indi-
cates the mucosal path of keratinocyte diVerentiation, i.e.
the type II keratin K4 and the type I keratin K13 (Moll et al.
1982b; Cooper et al. 1985). Immunohistochemical studies
using speciWc MAbs—such as MAb 6B10 against K4 (van
Muijen et al. 1986) and MAbs 1C7, 2D7 (van Muijen et al.
1986) and Ks13.1 (Moll et al. 1988b) against K13—
revealed the presence of K4 and K13 in the entire supraba-
sal compartment of mucosal stratiWed squamous epithelia,
whereas the basal compartment is positive for K5/K14.
Interestingly, K4/K13 is completely absent in the epidermis
and adnexal structures. Keratin K13 is also expressed in the
urothelium as a major component of the basal and interme-
diate cells whereas it is lost in the superWcial umbrella cells
(that switch on K20 expression; see above). Keratin K4 is
also—heterogeneously—expressed in columnar luminal
cells of the pseudostratiWed respiratory epithelium and in
the non-stratiWed simple epithelial cells of e.g. pancreatic
ducts (van Muijen et al. 1986; Moll 1993).
Functionally, K4 and K13 appear to be important partic-
ularly as components of mucosal stratiWed squamous epi-
thelia. Mutations in these keratins, lying in the helix
initiation or termination motifs (HIM or HTM, respec-
tively), have been shown to cause the hereditary disorder
white sponge nevus of Cannon (for references see Lane and
McLean 2004). This mucosal disorder presents with white
plaques mainly on the buccal mucosa, histologically show-
ing thickened spongy epithelium with hydropic swelling of
suprabasal epithelial cells. Here again, the clinical manifes-
tation of pathological alterations of keratins well reXects
their tissue distribution.
It is not surprising that squamous cell carcinomas
derived from the epidermis essentially lack K4 and K13
(Kuruc et al. 1989; for further references see Moll 1998).
However, in contrast to what might be expected, they are
not major components of, but are only focally and variably
expressed in squamous cell carcinomas of the head and
neck, with more pronounced expression in poorly diVeren-
tiated cases (Moll 1998). Instead, the predominant matura-
tion-associated keratins expressed by these tumors are the
hyperproliferative keratins K6 and 16 (see below, chapter
“Keratins as diagnostic markers in tumor pathology”). Cor-
responding to its characteristic expression in normal uro-
thelium, K13 is maintained—at least focally—in most
transitional cell carcinomas of the urinary tract (Moll et al.
1988b; for further references, see Moll 1998). K13 may be
part of a panel of markers (which also includes K20) useful
in the histological diagnosis of metastatic transitional cell
carcinomas (see below, chapter “Keratins as diagnostic
markers in tumor pathology”). As to adenocarcinomas, it is
noteworthy to mention the frequent expression of K4 in
ductal adenocarcinomas of the pancreas (Schüssler et al.
1992; Real et al. 1993; Moll 1998) and in a subpopulation
of poorly diVerentiated invasive ductal breast carcinomas
(Malzahn et al. 1998).
K76, K77: keratins with very special expression sites
K76 (previously designated K2p) is speciWcally expressed
in suprabasal cell layers of oral masticatory epithelium, i.e.
the slightly orthokeratinized stratiWed squamous epithelium
lining the gingiva and the hard palate (Collin et al. 1992b).
Because of the failure of speciWc antibodies for long time,
which are now available (PROGEN, Heidelberg, made by
L.L.), no tumor studies have been done yet.
The expression pattern of keratin K77 (previously desig-
nated K1b) was very surprising and extremely restricted.
This keratin is exclusively expressed in and restricted to the722 Histochem Cell Biol (2008) 129:705–733
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luminal cells of eccrine sweat gland ducts (Fig. 5a–d). All
other epithelia and glands tested so far, including apocrine
sweat gland, were negative (Langbein et al. 2005). Based
on the extensive investigation of the keratin pattern, new
aspects of eccrine sweat gland diVerentiation could be
achieved (Langbein et al. 2005 and supplemental data
therein). The high speciWcity of expression makes this kera-
tin recommendable for using as an “eccrine duct marker” in
tumor diagnostics. In a Wrst study, this assumption could be
conWrmed by the investigation of “eccrine” adnexal tumors
such as syringoma (Fig. 5e), poroma (Langbein et al. 2008)
and cylindroma (Fig. 5f).
K25, K26, K27, K28, K71, K72, K73, K74, K75: hair 
follicle-speciWc epithelial keratins
Only recently it has become clear that some of the epithelial
root sheaths of the hair follicle, the inner root sheath and
the companion layer, are unique by their expression of a
number of very special keratins (for review, see Langbein
and Schweizer 2005; Langbein et al. 2006; Schweizer et al.
2007). Over the years, these keratins were not detected
before by biochemical methods because of their quantita-
tive “under-representation” when compared to the masses
of hair or epidermal keratins in the tissue. The Wrst of these
new special keratins described was K75. This keratin was
originally called K6hf, with “hf” indicating its expression
site in the “hair follicle”, not knowing that this aspect of
designation would be unfeasible later. K75 (K6hf) is a type
II keratin and was, although closely related in its peptide
sequence to K5, following the principles of the former
keratin designation (cf. Collin et al. 1992a, b) by using the
electrophoretic properties, designated as a “K6” keratin
(Winter et al. 1998). K75 is speciWcally expressed in the
companion layer of the hair follicle (Fig. 6a, h, i), a thin
layer between the outer and the inner epithelial root sheath
(Winter et al. 1998). As the expression of this keratin as
monitored by its mRNA synthesis using in situ hybridiza-
tion starts from the bulbar matricial compartment of the
hair follicle and the protein is still existent in the upper
diVerentiated part where the K75 mRNA is no longer syn-
thesized, it was one Wrst but doubtless indication that this
structure is an own individual compartment of the hair folli-
cle and not the “innermost layer of the outer root sheath”
(see Winter et al. 1998; Langbein and Schweizer 2005).
The only further structures in which K75 has been detected
are the hair medulla of, e.g. beard hairs, the nail bed, and
fungiform papillae of the tongue (Wang et al. 2003; Perrin
2007; Langbein and Schweizer 2005). A mutation in K75
appears to predispose to the common hair disorder pseudo-
folliculitis barbae, which is characterized by ingrown beard
hairs with inXammation, induced by shaving (Winter et al.
2004; Schweizer et al. 2007), and to the loose anagen hair
syndrome (Chapalain et al. 2002). Immunostaining for K75
has been reported in trichoblastomas and basal cell carcino-
mas (Kurzen et al. 2001) and has recently been observed in
some squamoid cells of pilomatricomas (M. Divo, L. Lang-
bein and R. Moll, in preparation), indicating special focal
diVerentiation in these diverse cutaneous tumors. We have
recently found sparse and focal expression of K75 in cer-
tain squamous cell carcinomas of inner organs (M. Divo, L.
Langbein and R. Moll, in preparation).
A set of four type I keratins (K25–K28; previous desig-
nations K25irs1–K25irs4, see Table  1) and four type II
keratins (K71–K74; previous designations K6irs1–K6irs4,
see Table 1) is highly speciWc for the inner root sheath
(IRS) of the hair follicle (Fig. 6h, i). These IRS keratins are
diVerentially and partially sequentially expressed in the
various IRS compartments, the Henle layer, the Huxley
layer, and the IRS cuticle. The keratinocytes of all three
compartments synthesize the IRS keratins K71 (Fig. 6b, h,
i), K25, K27 and K28. K74 is restricted to the Huxley layer,
whereas K73, K72 (Fig. 6c, h, i) and K28 are sequentially
expressed in the IRS cuticle (Langbein et al. 2002, 2003,
2006; Langbein and Schweizer 2005; Fig. 6h, i). Otherwise,
no “classical” epithelial keratins were evidenced without
any doubts in the IRS and earlier reports most probably
showed (at that time not expected) cross-reaction of anti-
bodies with at least one of these IRS keratins (cf. Langbein
et al. 2006). Some of the IRS keratins—together with many
others—have also been found in the hair medulla (see
Schweizer et al. 2007 and Langbein et al., in preparation).
In mice, spontaneous hair disorders due to mutations in
K71 have been identiWed (for references, see Schweizer
et al. 2007). Human hair disorders related to the IRS kera-
tins have not yet been discovered. MonospeciWc antisera
against all of these keratins are available (PROGEN,
Heidelberg, Germany; Langbein et al. 2004, 2006).
K31, K32, K33a, K33b, K34, K35, K36, K37, K38, K39, 
K40, K81, K82, K83, K84, K85, K86: keratins of the hair 
Wber (hair keratins)
It is long known since the early period of keratin research
that in the (hard) material of hairs, wool, nails, claws and
feathers, the tremendous masses of keratin Wlaments (selec-
tion of the early literature: Odland 1953; Fraser et al. 1959;
Rogers and Clarke 1965; Orfanos and Ruska 1968) are
embedded in a matrix of cross-linking specialized keratin
associated proteins (KAPs) with more than 85 genes in
humans (for review, see Rogers et al. 2006). The special,
more sulfur-rich keratin proteins constituting these Wla-
ments are the “hard” or “trichocytic” keratins. Originally,
eight “major” (type I: Ha1-4, type II: Hb1-4) and two
“minor” (Hax, Hbx) keratins were distinguished (Heid et al.
1986, 1988a, b). In the last 10 years many more, namely 17Histochem Cell Biol (2008) 129:705–733 723
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members of this keratin subfamily have been identiWed Wrst
at their gene level (Rogers et al. 2004, 2005 and references
therein) which are now generally referred to as the hair ker-
atins (Langbein et al. 1999,  2001,  2007; Langbein and
Schweizer 2005; Schweizer et al. 2006; see also Table 1).
The conspicuous abundance of these proteins comprises
eleven type I hair keratins (K31–K40; previous designa-
tions Ha1–Ha8, Ka35, Ka36; Langbein et al. 1999, 2001,
2007, Langbein and Schweizer 2005; Schweizer et al.
2006; see also Table 1) and six type II hair keratins (K81–
K86; previous designations Hb1–Hb6; Langbein et al.
1999,  2001; Schweizer et al. 2006; see also Table 1;
Fig. 6h, i). In the hair, they exhibit diVerential, complex and
in many cases sequential expression patterns within the
cuticle and the cortex (Langbein et al. 1999, 2001, 2007;
Langbein and Schweizer 2005; Schweizer et al. 2007; for
medulla: Langbein et al., in preparation). K35 and K85
(Fig. 6d, h, i) are already expressed in the hair-forming
matrix of the cortex and the hair cuticle. The other hair ker-
atins [type I: K31, K33a, K33b, K34, K36, K38 (focally)
and K39 (including hair cuticle); type II: K81 and K86] are
sequentially switched on upon diVerentiation in the lower
hair cortex and in particular the large “bulk” of hair keratins
are expressed in the middle cortex (“keratinizing zone”) of
the ascending hair Wber (Fig. 6f, h, i). Furthermore, K32,
K83, K82 (Fig. 6e, h, i) and K40 are sequentially expressed
and restricted in the hair cuticle (Langbein and Schweizer
2005; Langbein et al. 2007). As exceptions, K37 was only
Fig. 6 ImmunoXuorescence 
labeling of hair follicle-speciWc 
and hair keratins. The hair folli-
cle-speciWc epithelial keratin 
K75 (a) is speciWcally found in 
the hair companion layer (cl) and 
in the medulla (med) of sexual 
(e.g. beard) hairs. K71 (b) is ex-
pressed in all compartments and 
K72 (c) in the cuticle (icu) of the 
hair inner root sheath (IRS). The 
hair keratin K85 (d) expression 
is found from the hair matrix to 
the upper cortex and the hair 
cuticle (cu), whereas K82 (e) is 
restricted to the hair cuticle. K86 
(f) is an example for hair kera-
tins expressed in the mid-to-up-
per hair cortex (co). g Hair 
keratin K81 is also expressed in 
the upper transitional cells of 
pilomatricoma. co cortex, dp 
dermal papilla, ORS outer root 
sheath. h, i Summary schemes of 
the expression of all hair and 
hair follicle-speciWc keratins in 
the human hair follicle. **K37 is 
found in the cortex of vellus 
hairs and medulla of sexual 
hairs. *K38 is heterogeneously 
expressed in the cortex. The ker-
atin genes are designated 
according to the new keratin 
nomenclature (Schweizer et al. 
2006)724 Histochem Cell Biol (2008) 129:705–733
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found in the cortex of vellus hairs and K84, although a typ-
ical hair keratin was not detected in the hairs but speciW-
cally in the Wliform papillae of the tongue (Langbein and
Schweizer 2005).
One has to keep in mind that out of the 54 human kera-
tins at least 26 (»50%) are expressed in the hair follicle.
Therefore, it is most amazing that this extraordinary com-
plex structure—built up by a stratiWed outer root sheath, the
companion layer, the inner root sheath comprising Henle,
Huxley and IRS-cuticle layers, the hair cuticle, cortex, and
sometimes a medulla—diVerentiate from cells of an
undiVerentiated and pluripotent “germinative cell pool”
(Fig. 6a, h, i). There must exist an incredible “Wne-tuning”
in the regulation of gene expression when e.g. one cell
diVerentiates into the IRS-cuticle and the directly neighbor-
ing cell builds up the hair cuticle, both structures being only
one cell wide. Unfortunately, up to now, our knowledge on
this most complex regulation of hair keratin gene expres-
sion is rather fragmentary.
Hair keratins are also prominently expressed in the nail
matrix and nail bed and contribute to the formation of the
hard tissue of the nail plate (Perrin et al. 2004; Perrin
2007). Moreover, in the 1980s hair keratins have been addi-
tionally detected by immunohistochemistry in Wliform
papillae of the tongue and, intriguingly, in reticulum cells
and Hassall’s corpuscles of the thymus (Heid et al. 1988b).
Some human mutations aVecting hair keratin genes
have been recognized. The most well-known of these is
the congenital hair disease monilethrix, characterized by
deformed hair shafts with a beaded appearance. Causa-
tive mutations for this disorder have been identiWed in the
hair keratins K86, K81, and rarely in K83 (Winter et al.
1997; for further references, see Schweizer et al. 2007),
all of which are expressed in the cortex of hair shafts and
thus indicating that monilethrix is a disease of the hair
cortex. A further, rare disease recently found to be related
to a distinct mutation in the type II hair keratin K85 is
ectodermal dysplasia of hair and nail type, characterized
by total alopecia and severe nail dystrophy (Naeem et al.
2006). The expression of K85 already in the hair matrix
from which hair Wber formation starts (Schweizer et al.
2007) may explain the severe hair phenotype of these
patients.
As to tumors, hair keratins have—up to now—only been
detected in pilomatricomas (Moll et al. 1988a; Régnier
et al.  1997) which are regarded as originating from hair
matrix and undergoing true hair diVerentiation. The com-
plex hair keratin expression in benign and malignant pilo-
matricoma (Cribier et al. 2001, 2004, 2006) conWrms this
notion at the molecular level. MonospeciWc antisera against
all of these keratins are available (PROGEN, Heidelberg,
Germany; Langbein et al. 2004, 2006).
K23, K24, K78, K79, K80: keratins with still unknown 
expression pattern
These Wve, very diVerent keratins complete the family of
human keratin proteins. In principle, mainly the gene and
cDNA sequences for the type I keratins K23 (Zhang et al.
2001) and K24 and the type II keratins K78 (formerly
K5b), K79 (formerly K6l), and K80 (formerly Kb20)
(Rogers et al. 2004, 2005) are known up to now. Unfortu-
nately only very vague and preliminary (or no) expres-
sion data are available from Northern blot analyses,
suggesting their expression in tongue (K78, K80) and
skin (K79), respectively (Rogers et al. 2005). As they
were obviously “overlooked” in former studies, their
expression might be restricted to very special epithelia,
distinct cellular diVerentiation stages or even transient
expression phases. The investigation of the detailed
expression pattern of these keratins will be one of the
most urgent studies in this Weld.
Keratins as diagnostic markers in tumor pathology
One of the important Welds of “application” of keratins
(making use of the knowledge of their high number of gene
family members combined with their special and character-
istic expression patterns in distinct cell types, diVerentiation
stages or functional states) is their use—aided by speciWc
antibodies—as immunohistochemical markers in diagnos-
tic tumor pathology. Epithelial tumors maintain—at least
widely—speciWc features of the keratin expression patterns
of the respective cell type of origin. Thus, in cases which on
the basis of clinical data and conventional histopathology
remain unclear, keratin typing may help to correctly iden-
tify and classify the tumor entity present. Keratin proWling
is especially valuable for carcinomas of poorly diVerenti-
ated histology, for carcinomas spreading over several
organs, and in particular for metastases of an unknown pri-
mary tumor. Of the 54 human keratins, only a relatively
small panel has attained diagnostic importance up to now,
which might grow further with time and respective studies
by including the keratins described within the last years.
The carefully selected use of diagnostically relevant keratin
antibodies—if appropriate, as part of a panel together with
other tumor type markers—has become diagnostic standard
in state-of-the-art clinical pathology (for recent overviews,
see Chu and Weiss 2002b; Dabbs 2006). In the previous
chapter on the individual keratins, some data on their
expression patterns in tumors have already been presented.
In the following, key diagnostic features of keratin typing
concerning important tumor entities will be brieXy summa-
rized.Histochem Cell Biol (2008) 129:705–733 725
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Adenocarcinomas
Adenocarcinomas are one of the largest groups of human
malignant tumors and may arise in many organs and tis-
sues. They comprise more than one-half of cases of can-
cer with unknown primary tumor. The identiWcation of
the speciWc origin—e.g. colon, ovary, pancreas, or lung—
has become therapeutically important since eVective che-
motherapy schedules may be vastly diVerent. As a group,
adenocarcinomas are characterized by the predominance
of simple-epithelial keratins, notably K8, K18 and K19,
whereas K7 and K20 are variably expressed. It is this var-
iability which may be diagnostically exploited, and thus
staining for both K7 and K20 is the current practice
resulting in diVerent K7/K20 phenotypes (Table 3). The
highest diagnostic signiWcance of keratin typing is true
for colorectal adenocarcinomas which—like the normal
mucosa—almost always remain K20-positive (Fig. 3d).
Most cases, including metastases, exhibit a K7¡/K20+
phenotype (Fig. 3c, d) or express K7 at lower level as
compared to K20 (Moll et al. 1992; Miettinen 1995; for
further references, see Moll 1998, Chu and Weiss 2002b).
K7 co-expression has been detected more frequently in
advanced colorectal cancers (Hernandez et al. 2005).
Although so characteristic of colorectal tumors, K20 may
in certain situations be reduced. Thus, reduced expression
of K20 has been found in a speciWc subset of colorectal
carcinomas with high levels of microsatellite instability
(McGregor et al. 2004); notably, K7 expression remained
low in these tumors. Since K20 is a diVerentiation marker
its reduction or even loss may also be due to dediVerenti-
ation. In a large tissue microarray study, reduced expres-
sion of K8 and K20 was found to be associated with
shorter patients’ survival, possibly on the basis of epithe-
lial-mesenchymal transition (Knösel et al. 2006). Adeno-
carcinomas of the stomach usually show heterogeneous
expression of both K7 and K20, the latter being rather
variable but yet expressed in the majority of cases (Moll
1998, Chu and Weiss 2002b). No systematic diVerences
between intestinal and diVuse/signet ring cell carcinomas
have been described. In adenocarcinomas of the pan-
creas and the biliary tract, there is usually a clear pre-
dominance of K7 (Fig. 3e) together with variable and
focal (often minor) expression of K20 in up to 75% of
cases (Fig. 3f, Moll 1998; Chu and Weiss 2002b). Ductal
adenocarcinomas of the pancreas in addition often
express certain stratiWed-epithelial keratins, most notably
K4 and K17 (Schüssler et al. 1992; Real et al. 1993; Moll
1998). Finally, a K7+/K20¡ phenotype is characteristic of
adenocarcinomas of the ovary (except for the mucinous
type), the endometrium and the lung. Endometrial adeno-
carcinomas often focally co-express certain stratiWed-epi-
thelial keratins including K5, reXecting the potential of
the tumor cells for stratiWcation to develop squamous
metaplasia.
Like other adenocarcinomas, most breast carcinomas
constitutively express K8, K18 and K19 (Altmannsberger
et al. 1986; Malzahn et al. 1998). In some studies, however,
a high level of K8 or K18 immunostaining, as detected by
certain monoclonal antibodies, has been correlated with
favorable prognosis and reduced or absent staining was
associated with unfavorable outcome (Takei et al. 1995;
Schaller et al. 1996; WoelXe et al. 2004). Microarray-based
expression proWling of breast carcinomas has led to the
deWnition of distinct subgroups. One of these has been des-
ignated as basal-like group (Sørlie et al. 2001) which is
characterized by relatively poor prognosis. Interestingly,
the typical expression proWle of the basal-like cancers
includes the basal cell-typical keratins K5, K14 and K17.
Several older reports have already described the presence
of such keratins in a subpopulation of breast carcinomas
(Moll et al. 1983; Wetzels et al. 1991), and some did
already point to a negative prognostic signiWcance of basal
cell keratin expression in invasive ductal breast cancers
(Dairkee et al. 1987; Malzahn et al.1998). This has now
been conWrmed and extended by the growing body of
recent microarray data, allowing to deWne a subgroup of
sporadic breast cancers which exhibit bad prognosis and
association with BRCA1 mutation or dysfunction (Guster-
son et al. 2005; Diaz et al. 2007). For the recognition of this
subgroup, immunostaining for keratins such as K5 may
achieve importance (van de Rijn et al. 2002; for further ref-
erences, see Gusterson et al. 2005).
The diVerent subtypes of renal cell carcinomas (RCCs)
exhibit some characteristic features in keratin expression
which may support the precise classiWcation of these
tumors (Thoenes et al. 1988; Moll 1993; Chu and Weiss
2002b; Skinnider et al. 2005; Liu et al. 2007). Thus, con-
ventional (clear cell) RCCs express a simple keratin pat-
tern of mainly K8/K18 together with variable, mostly
minor expression of K19. In contrast, the papillary sub-
type of RCC is characterized by strong K19 expression as
well as K7 expression in addition to the basic pair K8/
K18. Chromophobe RCCs, on the other hand, typically
express K7 (but little K19) in addition to K8/K18 (Tho-
enes et al. 1988). The benign oncocytomas, which histo-
logically may resemble chromophobe RCC, are mostly
K7-negative (Liu et al. 2007). The peculiar co-expression,
together with keratins, of the mesenchymal intermediate
Wlament protein vimentin in conventional (clear cell) and
papillary RCCs but not in chromophobe RCCs and
oncocytomas is another feature valuable in diVerential
diagnosis. Another tumor category with characteristic
co-expression of keratins and vimentin are malignant
mesotheliomas. The epithelial type may be diYcult to dis-
tinguish histologically from adenocarcinomas (e.g. pleural726 Histochem Cell Biol (2008) 129:705–733
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involvement by pulmonary adenocarcinomas or pleural/
peritoneal metastases of adenocarcinomas of various ori-
gins). In contrast to most adenocarcinomas, epithelial
mesotheliomas consistently express keratinocyte-type ker-
atins, notably K5, in addition to keratins K8, K18, K19,
and K7 typical for simple epithelia (Moll et al. 1989;
Ordonez 1998; Chu and Weiss 2002a; Yaziji et al. 2006).
Thus, in recent years, K5 has been included in the battery
of useful mesothelioma markers.
Neuroendocrine tumors
Neuroendocrine tumors, a large and heterogeneous tumor
group, are generally characterized by the expression of ker-
atins typical of simple epithelia (notably K8, K18, and—
more variably—K19) and the complete lack of keratins K5/
K14 typically found in stratiWed epithelia. Particularly
interesting in a diagnostic respect is the well-proven value
of K20 as a consistent marker of Merkel cell carcinomas of
the skin, allowing their delineation from metastatic small
cell neuroendocrine carcinomas arising at other sites such
as small cell lung carcinoma which—although morphologi-
cally similar—consistently lack K20 (Moll et al. 1992;
Cheuk et al. 2001). Another interesting recent issue con-
cerns endocrine tumors of the pancreas. Several studies
suggest that the expression of K19 in these tumors may be
correlated with a poor prognosis (Schmitt et al. 2007; La
Rosa et al. 2007).
Transitional cell carcinomas
The urothelium exhibits a unique, complex pattern of kera-
tin expression. K8, K18, K19, and K7 are expressed in all
cell layers. K5 and K17 are restricted to the basal cell
layer. Particularly characteristic are K13 expressed in the
basal and intermediate cell layers and K20 speciWc for the
superWcial (umbrella) cell layer. This urothelial keratin
pattern is relatively well conserved in noninvasive and
invasive transitional cell carcinomas (TCCs) (for detailed
reviews, see Moll 1998; Southgate et al. 1999). K20 has
been found to be retained in »80% of TCCs (Moll et al.
1992). Indeed, the combined presence of keratins K8/K18
(as well as K7 and K19) typical for simple epithelia
together with K13 and K20 in a tumor is characteristic of
urothelial origin, although K13 may be reduced or lost in
poorly diVerentiated TCCs. Squamous metaplasia may
modify the keratin expression pattern. Particularly inter-
esting are the recent, prognostically relevant Wndings that
noninvasive papillary TCCs may exhibit a normal K20
pattern (predominantly superWcial) or an abnormal K20
pattern (all cell layers or negative) and that the normal pat-
tern is predictive of tumor non-recurrence (Southgate et al.
1999).
Squamous cell carcinomas
Squamous cell carcinomas of diVerent sites of origin are
generally characterized by a predominance of stratiWed-epi-
thelial/keratinocyte-type keratins but may co-express cer-
tain simple-epithelial keratins (for details, see Moll 1998).
Most of these tumors strongly express the keratins K5
(Fig. 4c, e), K14 and K17 normally found in the basal layer
as well as the keratins K6 (Fig. 4d) and K16 characteristic
for hyperproliferative keratinocytes. Focally, there may be
expression of K1/K10 (particularly in higher diVerentiated
tumor cells which can end in the formation of horn pearls),
and—to a lesser extent—K4 and K13. The co-expression of
simple epithelia-typical keratins comprises K8, K18, and
K19, and diVerent studies have suggested that this co-
expression seems to be more pronounced in poorly diVeren-
tiated squamous cell carcinomas (for references, see Moll
1998). Recently it has been demonstrated that in squamous
cell carcinomas of the oral cavity the expression of K8 and
K18 is an independent prognostic marker and indicates a
decreased overall and progression-free survival (Fillies
et al. 2006).
In summary, stratiWed-epithelial keratins, in particular
K5 and K6, are useful as general markers for squamous cell
carcinomas in histologically uncertain, poorly diVerenti-
ated, or metastatic tumor cases. Although certain diVer-
ences between the keratin expression patterns of squamous
cell carcinomas from diVerent sites of origin have been
noted, it is not yet possible to use keratins as speciWc site
markers in cases of unclear metastases (Moll 1998).
Perspectives
In the past 10 years, our knowledge on keratins has tremen-
dously increased, regarding their molecular and cell biol-
ogy as well as their application as markers in pathological
diagnosis. The introduction of a new consensus nomencla-
ture (Schweizer et al. 2006), which for the common (non-
hair follicle speciWc) epithelial keratins widely conserves
the older names established in the literature, makes this
complex Weld much clearer than before and will facilitate
future research. Today much is known about the structural
functions of keratins, as proven by a wealth of human
hereditary keratin diseases and transgenic mouse models.
However, numerous questions still need to be answered,
particularly concerning the regulatory functions of keratins.
As reviewed in this article, recent experimental studies
have pointed to newly recognized roles of certain keratins
in apoptosis, cell growth, tissue polarity, wound response,
and tissue remodeling. First, speciWc signaling pathways
have already been described which seem to be associated
with distinct keratins. The question of whether keratinsHistochem Cell Biol (2008) 129:705–733 727
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might play a role in malignant transformation is particularly
exciting, but at present a causal role in tumorigenesis has
not been established for any keratin (for review, see Magin
et al. 2007). However, keratins may in fact be linked to the
cell cycle machinery (Margolis et al. 2006). Future research
will hopefully answer the question why the human organ-
ism actually needs 54 diVerent keratin proteins, all of which
in the Wrst instance form the seemingly “primitive”, uni-
form structure of a 10 nm intermediate Wlament—although
with peculiarities in the head and tail domains of their sin-
gle molecular components.
One may also expect for the future that the diagnostic
application of keratins, although already established in
tumor pathology, will be further reWned and extended.
Examples of very recent new developments in tumor classi-
Wcation are the recognition of the basal-like subtype of
breast cancer on the basis of the expression of K5 and the
prognostic relevance of K19 in endocrine pancreatic tumors.
At the moment, the panel of keratins introduced into routine
diagnosis as histopathological tumor markers is distinctly
small, essentially consisting of K5, K7, K8/K18, K19, and
K20. Furthermore, the expression patterns of a battery of
special keratins were detected only in the last few years and
these keratins are just started to be involved into tumor diag-
nostic studies. Not to forget that at the time 5 out of the 54
human keratins are still uncharacterized in their expression
sites and patterns and possibly, their expression in neoplasia
might have a potential as diagnostic markers. Since all kera-
tins have an exquisite cell type- and diVerentiation stage-
speciWc regulation and expression pattern, it might well be
that upon future research further keratins will be introduced
as markers for certain diagnostic questions in pathology to
widen and to reWne the diagnostic potential of keratins.
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